The latest update is out from Rohto Pharmaceutical Co ( (JP:4527) ).
Rohto Pharmaceutical Co., Ltd. announced the completion of its share repurchase program, acquiring 2,174,300 shares at a total cost of approximately ¥5 billion. This strategic move aims to enhance return on equity and earnings per share, while also facilitating smoother fundraising efforts related to the issuance of Zero Coupon Convertible Bonds due in 2032, potentially strengthening the company’s financial position and market standing.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of healthcare products, including over-the-counter medications, skincare products, and health supplements. The company is known for its innovative solutions and strong market presence in both domestic and international markets.
YTD Price Performance: -14.08%
Average Trading Volume: 5,490
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.55B
Find detailed analytics on 4527 stock on TipRanks’ Stock Analysis page.